Modality
Bispecific Ab
MOA
GLP-1ag
Target
EGFR
Pathway
PD-1/PD-L1
MelanomaPompeProstate Ca
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
Oct 2018
→ Oct 2030
Phase 2Current
NCT08773298
251 pts·Prostate Ca
2022-07→2030-10·Not yet recruiting
NCT06670305
2,848 pts·Melanoma
2018-10→2025-06·Completed
3,099 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-06-219mo agoPh2 Data· Melanoma
2030-10-164.5y awayPh2 Data· Prostate Ca
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Complet…
P2
Not yet…
Catalysts
Ph2 Data
2025-06-21 · 9mo ago
Melanoma
Ph2 Data
2030-10-16 · 4.5y away
Prostate Ca
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08773298 | Phase 2 | Prostate Ca | Not yet recr... | 251 | CR |
| NCT06670305 | Phase 2 | Melanoma | Completed | 2848 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR | |
| RCU-2903 | Arcus Bio | NDA/BLA | EGFR |